By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

More than 4,400 lawsuits have been filed since millions of Americans embraced GLP-1 drugs like Ozempic, Wegovy and Mounjaro ...

According to the Centers for Disease Control and Prevention, 41.9 percent of U.S. adults were obese from 2017 to 2020.

Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? Novo Nordisk's weight ...

Serena Williams said that roughly a year after starting a weight loss drug, she is the healthiest she has ever been and has ...

A US mum says a new Wegovy weight-loss pill has helped restart her progress after injections proved too expensive. Sharon Vickers, 46, paid $149 a month for the tablets after her weight loss stalled ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN, Feb 4 (Reuters) - Novo Nordisk's shares plunged as much as 20% ...

Last year, there was a 15% annual increase in the operations and surgeons want more research.

Symptoms to look out for include severe pain in the stomach and back which does not go away.

The stock tumbled 19% at the opening bell in Copenhagen after its outlook for the year ahead disappointed investors.

Skye Bioscience reports Phase 2a data showing nimacimab plus semaglutide led to over 22% weight loss at 52 weeks, with lower ...

Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% ...